LYON, France, Dec. 8 /PRNewswire-FirstCall/ -- EDAP TMS S.A. will host a launch event for its Ablatherm-HIFU treatment of localized prostate cancer at Guys Hospital in London on Wednesday, December 14, 2005. Members of the financial community and media are invited to attend. The event will include two sessions, each of which will offer the opportunity to learn about Ablatherm-HIFU treatment of localized prostate cancer, interact with local doctors and patients regarding their treatment experiences, and examine the Ablatherm unit in an operating theater environment.
Those interested in attending should RSVP in advance to Matt Kreps, Halliburton Investor Relations (+1 972 458 8000 - mkreps@halliburtonir.com ). Detailed schedules and background information will be available to those attending.
Hugues de Bantel, CEO of EDAP, commented: “Ablatherm-HIFU treatment is a unique procedure in that it is minimally invasive, offers the patient a rapid recovery measured in days, not weeks, and is proven as effective as other treatment modalities, with lower occurrence of unpleasant side effects. We are pleased to bring this treatment to the United Kingdom and will be adding centers in several locations over the coming months. This will be to the benefit of patients seeking a treatment more in line with their medical needs or lifestyle and doctors seeking a treatment for difficult cases or even recurrence of cancer following a prior treatment which may limit or preclude the patient’s options.”
Prostate cancer is the second most common malignancy in males worldwide after lung cancer. Incidence rates vary in different countries, with most European countries reporting between 30 and 50 new cases diagnosed every year per 100,000 men (35,000 new cases in the UK per year). These numbers are increasing due to earlier diagnostic of the pathology and an increase in the mean male age.
About EDAP TMS S.A.
EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. The company is also developing this technology for the treatment of certain other types of tumors. EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).
For more information on the Company, contact the Investor Relations Dept by phone at +33 (0)4 78 26 40 46 or see the Company’s Web site at: http://www.edap-tms.com .
This press release contains, in addition to historical information, forward-looking statements that involve risks and uncertainties. These include statements regarding the Company’s growth and expansion plans. Such statements are based on management’s current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in the forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company’s filings with the Securities and Exchange Commission.
CONTACT: EDAP TMS S.A. Hugues de Bantel - Philippe Chauveau Blandine Confort +33 4 78 26 40 46 Halliburton Investor Relations Matt Kreps - Geralyn DeBusk +1 972 458 8000
EDAP TMS S.A.
CONTACT: Hugues de Bantel, Philippe Chauveau, or Blandine Confort, all ofEDAP TMS S.A., +33-4-78-26-40-46; or Matt Kreps or Geralyn DeBusk, both ofHalliburton Investor Relations, +1-972-458-8000, for EDAP TMS S.A.
Web site: http://www.edap-tms.com/
